An ongoing clinical investigation called the COMBINE-KIDNEY trial compares the effects of monotherapy (using either medication alone) and combination therapy (using an SGLT2 inhibitor plus a GLP-1RAs) on the rate of eGFR decline in individuals with CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.